UBS Group
STOK icon

UBS Group’s Stoke Therapeutics STOK Stock Holding History

UBS Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-31,000
Closed -$1.2M – 9800
2021
Q1 		$1.2M Buy
31,000
+9,100
+42% +$518K ﹤0.01% 4074
2020
Q4 		$1.36M Buy
+21,900
New +$1M ﹤0.01% 3760

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

UBS Group's STOK Position: Q1 2026 in Review

UBS Group reduced its Stoke Therapeutics (STOK) stake by 6.7% in Q1 2026, selling an estimated $374K and leaving 158,304 shares worth $5.15M. The position accounts for ﹤0.01% of the portfolio, ranked #4057.

UBS Group first reported a position in STOK in Q2 2019 and has held it in 24 quarters since. The position peaked at $7.19M in Q3 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • UBS Group held 158,304 shares of Stoke Therapeutics worth $5.15M as of Q1 2026.
  • UBS Group sold 11,409 Stoke Therapeutics shares in Q1 2026, an estimated $374K.
  • Stoke Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4057 holding.
  • UBS Group first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 24 quarters since.
  • UBS Group's Stoke Therapeutics position peaked at $7.19M in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.